secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0000950170-24-117318
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine presents positive Phase 1b data for DISC-0974 in CKD anemia at ASN Kidney Week
--------------------------------------------------------------------------------

- Dose-dependent hepcidin reduction >75% from baseline at highest dose (60 mg); transferrin saturation up to 3x baseline.
- Mean hemoglobin increase of +0.55 g/dL at 60 mg vs +0.21 g/dL placebo; individual max increase +1.8 g/dL.
- All treatment-related adverse events Grade 1 or 2; majority unrelated to DISC-0974; acceptable safety profile.
- Data from SAD cohorts (28, 40, 60 mg) in Stage 2-5 NDD-CKD anemia; dose escalation and multiple-dose portion ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000095017024117318/0000950170-24-117318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000095017024117318/iron-20241025.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-117318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer